Drugs / 131I-F16SIP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01240720 | Sep 2008 → Nov 2011 | cancer | Philogen S.p.A. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 131I-F16SIP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01240720 ↗ |
| Modality | Monoclonal antibody | “Tumour Targeting Human 131I-F16SIP Monoclonal Antibody” NCT01240720 ↗ |
| Route | Intravenous | “will be administered intravenously (I.V).” NCT01240720 ↗ |